• Explore /
  • Poster
  • / Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma.

Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma.

Abstract Poster

Authors

null

Mark R. Middleton

University of Oxford, Oxford, United Kingdom

Mark R. Middleton , Neil Matthew Steven , Thomas Jeff Evans , Jeffrey R. Infante , Mario Sznol , Clive Mulatero , Omid Hamid , Alexander Noor Shoushtari , William Shingler , Andy Johnson , Sanjay Patel , Debbie Parker , David Krige , Cheryl McAlpine , Christina Marie Coughlin , Namir J Hassan , Bent K Jakobsen , Philippa Corrie

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Other

Clinical Trial Registration Number

NCT01211262

Citation

J Clin Oncol 34, 2016 (suppl; abstr 3016)

DOI

10.1200/JCO.2016.34.15_suppl.3016

Abstract #

3016

Poster Bd #

338

Abstract Disclosures

Similar Posters

First Author: Mark R. Middleton

First Author: Mark R. Middleton

First Author: George R. Blumenschein, Jr.

First Author: Takami Sato